Table 1.
Patient characteristics at baseline
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | Total (% or median) | |
|---|---|---|---|---|---|---|---|---|
| Patient characteristics | ||||||||
| Sex (female%) | F | F | M | M | M | M | 33% | |
| Age at 1st MSC | 12.1 | 15.9 | 09.4 | 14.0 | 16.8 | 16.2 | 15.0 yrs | |
| Disease duration at 1st MSC | 4.4 | 9.2 | 6.7 | 13.3 | 9.3 | 12.7 | 9.2 yrs | |
| Extended oligo-articular | ✓ | ✓ | 33% | |||||
| Poly-articular RF- | ✓ | ✓ | ✓ | 50% | ||||
| Systemic | ✓ | 17% | ||||||
| Antinuclear antibodies + | - | - | - | + | + | - | 33% | |
| Uveitis ever | - | - | - | - | - | - | 0% | |
| JADI-Articular damage | 1 | 7 | 18 | 1 | 12 | 0 | 4 | |
| JADI-Extra-articular damage | 1 | 0 | 1 | 1 | 3 | 7 | 1 | |
| Medication history (duration in months) | ||||||||
| IA steroids (ever) | ✓ | ✓ | ✓ | ✓ | ||||
| Corticosteroids | MP pulse i.v. | 3x | 7x | |||||
| Oral steroids | 70 | 67 | 18 | 15 | 153 | 43 | ||
| MTX | 43 | 16 | 59 | 152 | 81 | 153 | 70 | |
| Sulfasalazine | 6 | 41 | ||||||
| sDMARDs | Leflunomide | 22 | ||||||
| Ciclosporine | 2 | |||||||
| Thalidomide | 34 | |||||||
| Alkylating agents | Cyclophosphamide | 9 | ||||||
| Kinase inhibitor | Tofacitinib | 3 | ||||||
| Abatacept | 5 | 19 | 3 | 7 | 4 | |||
| Anakinra | 1 | 5 | ||||||
| Adalimumab | 30 | 11 | 1 | 9 | 46 | 10 | ||
| Certolizumab | 4 | |||||||
| Biologicals | Canakinumab | 2 | 3 | |||||
| Etanercept | 18 | 8 | 100 | 15 | 3 | 12 | ||
| Golimumab | 23 | |||||||
| Infliximab | 3 | |||||||
| Rituximab | 6 | |||||||
| Tocilizumab | 6 | 3 | 3 | 4 | 2 | 75 | 4 | |
| aHSCT (CYC & ATG) | ✓ | |||||||
| Last time biological prior to MSC (weeks) | 5 | 31 | 12a | 5 | 17 | 2 | 9 | |
| Concurrent medication use | ||||||||
| MTX (mg/wk) | 25 | 7.5 | 25 | |||||
| Prednisolone (mg/d) | 10 | 13 | 5 | 14 | 2 | 8 | ||
The underlined biologicals are the ones last used by that specific patient.
a
This patient used his last tocilizumab as 2-weekly subcutaneous injections.
aHSCT: autologous haematopoietic stem cell transplant; ATG: antithymocyte globulines; JADI: Juvenile Arthritis Damage Index; Mo: months; MP: methylprednisolone; MSC: mesenchymal stromal cells; sDMARDs: synthetic DMARDs.